A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-07 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Data from Erection and Maintenance Manual for P-51D and P-51K, P-51 Tactical Planning Characteristics & Performance Chart, The Great Book of Fighters, and Quest for PerformanceGeneral characteristics Crew: 1 Length: 32 ft 3 in (9.83 m) Wingspan: 37 ft 0 in (11.28 m) Height: 13 ft 4.5 in (4.077 m) tail wheel on ground, vertical propeller blade Wing area: 235 sq ft (21.8 m2) Aspect ratio: 5.83 Airfoil: NAA/NACA 45–100 Empty weight: 7,635 lb (3,463 kg) Gross weight: 9,200 lb (4,173 kg) Max takeoff weight: 12,100 lb (5,490 kg) Fuel capacity: 269 US gal (224 imp gal; 1,020 L) Zero-lift drag coefficient: 0.0163 Drag area: 3.80 sqft (0.35 m²) Powerplant: 1 × Packard (Rolls-Royce) V-1650-7 Merlin 12-cylinder liquid cooled engine, 1,490 hp (1,110 kW) at 3,000 rpm; 1,720 hp (1,280 kW) at WEP Propellers: 4-bladed Hamilton Standard constant-speed, variable-pitch, 11 ft 2 in (3.40 m) diameter Performance
==== MeSH D12.125.481 – glycine ==== MeSH D12.125.481.100 – allylglycine MeSH D12.125.481.700 – n-substituted glycines MeSH D12.125.481.700.249 – glycocholic acid MeSH D12.125.481.700.249.420 – glycodeoxycholic acid MeSH D12.125.481.700.249.420.400 – glycochenodeoxycholic acid MeSH D12.125.481.700.374 – sarcosine MeSH D12.125.481.700.500 – thiopronine MeSH D12.125.481.700.750 – thiorphan
Studies have measured δ34S values of bone collagen, though the interpretation of these values was not reliable until quality criteria were published in 2009. Though bone collagen is abundant in skeletal remains, less than 1% of the tissue is made of sulfur, making it imperative that these studies carefully assess the meaning of bone collagen δ34S values.
Sources: en.wikipedia.org
== Examples == The following is a list of human proteins containing the protein kinase domain: AAK1 ; AATK ; ABL1 ; ABL2 ; ACVR1 ; ACVR1B ; ACVR1C ; ACVR2A ; ACVR2B ; ACVRL1 ; AKT1 ; AKT2 ; AKT3 ; ALK ; AMHR2 ; ANKK1 ; ARAF ; AURKA ; AURKB ; AURKC ; AXL ; BLK ; BMP2K ; BMPR1A ; BMPR1B ; BMPR2 ; BMX ; BRAF ; BRSK1 ; BRSK2 ; BTK ; BUB1 ; BUB1B ; CAMK1 ; CAMK1D ; CAMK1G ; CAMK2A ; CAMK2B ; CAMK2D ; CAMK2G ; CAMK4 ; CAMKK1 ; CAMKK2 ; CAMKV ; CASK ; CDC42BPA ; CDC42BPB ; CDC42BPG ; CDC7 ; CDK1 ; CDK10 ; CDK11A ; CDK11B ; CDK12 ; CDK13 ; CDK14 ; CDK15 ; CDK16 ; CDK17 ; CDK18 ; CDK19 ; CDK2 ; CDK20 ; CDK3 ; CDK4 ; CDK5 ; CDK6 ; CDK7 ; CDK8 ; CDK9 ; CDKL1 ; CDKL2 ; CDKL3 ; CDKL4 ; CDKL5 ; CHEK1 ; CHEK2 ; CHUK ; CIT ; CLK1 ; CLK2 ; CLK3 ; CLK4 ; CSF1R ; CSK ; CSNK1A1 ; CSNK1A1L ; CSNK1D ; CSNK1E ; CSNK1G1 ; CSNK1G2 ; CSNK1G3 ; CSNK2A1 ; CSNK2A2 ; CSNK2A3 ; DAPK1 ; DAPK2 ; DAPK3 ; DCLK1 ; DCLK2 ; DCLK3 ; DDR1 ; DDR2 ; DMPK ; DSTYK ; DYRK1A ; DYRK1B ; DYRK2 ; DYRK3 ; DYRK4 ; EGFR ; EIF2AK1 ; EIF2AK2 ; EIF2AK3 ; EIF2AK4 ; EPHA1 ; EPHA10 ; EPHA2 ; EPHA3 ; EPHA4 ; EPHA5 ; EPHA6 ; EPHA7 ; EPHA8 ; EPHB1 ; EPHB2 ; EPHB3 ; EPHB4 ; EPHB6 ; ERBB2 ; ERBB3 ; ERBB4 ; ERN1 ; ERN2 ; FER ; FES ; FGFR1 ; FGFR2 ; FGFR3 ; FGFR4 ; FGR ; FLT1 ; FLT3 ; FLT4 ; FRK ; FYN ; GAK ; GRK1 ; GRK2 ; GRK3 ; GRK4 ; GRK5 ; GRK6 ; GRK7 ; GSG2 ; GSK3A ; GSK3B ; GUCY2C ; GUCY2D ; GUCY2F ; HCK ; HIPK1 ; HIPK2 ; HIPK3 ; HIPK4 ; HUNK ; ICK ; IGF1R ; IKBKB ; IKBKE ; ILK ; INSR ; INSRR ; IRAK1 ; IRAK2 ; IRAK3 ; IRAK4 ; ITK ; JAK1 ; JAK2 ; JAK3 ; KALRN ; KDR ; KIT ; KSR1 ; KSR2 ; LATS1 ; LATS2 ; LCK ; LIMK1 ; LIMK2 ; LMTK2 ; LMTK3 ; LRRK1 ; LRRK2 ; LTK ; LYN ; MAK ; MAP2K1 ; MAP2K2 ; MAP2K3 ; MAP2K4 ; MAP2K5 ; MAP2K6 ; MAP2K7 ; MAP3K1 ; MAP3K10 ; MAP3K11 ; MAP3K12 ; MAP3K13 ; MAP3K14 ; MAP3K15 ; MAP3K19 ; MAP3K2 ; MAP3K20 ; MAP3K21 ; MAP3K3 ; MAP3K4 ; MAP3K5 ; MAP3K6 ; MAP3K7 ; MAP3K8 ; MAP3K9 ; MAP4K1 ; MAP4K2 ; MAP4K3 ; MAP4K4 ; MAP4K5 ; MAPK1 ; MAPK10 ; MAPK11 ; MAPK12 ; MAPK13 ; MAPK14 ; MAPK15 ; MAPK3 ; MAPK4 ; MAPK6 ; MAPK7 ; MAPK8 ; MAPK9 ; MAPKAPK2 ; MAPKAPK3 ; MAPKAPK5 ; MARK1 ; MARK2 ; MARK3 ; MARK4 ; MAST1 ; MAST2 ; MAST3 ; MAST4 ; MASTL ; MATK ; MELK ; MERTK ; MET ; MINK1 ; MKNK1 ; MKNK2 ; MLKL ; MOK ; MOS ; MST1R ; MUSK ; MYLK ; MYLK2 ; MYLK3 ; MYLK4 ; MYO3A ; MYO3B ; NEK1 ; NEK10 ; NEK11 ; NEK2 ; NEK3 ; NEK4 ; NEK5 ; NEK6 ; NEK7 ; NEK8 ; NEK9 ; NIM1K ; NLK ; NPR1 ; NPR2 ; NRBP1 ; NRBP2 ; NRK ; NTRK1 ; NTRK2 ; NTRK3 ; NUAK1 ; NUAK2 ; OBSCN ; OXSR1 ; PAK1 ; PAK2 ; PAK3 ; PAK4 ; PAK5 ; PAK6 ; PAN3 ; PASK ; PBK ; PDGFRA ; PDGFRB ; PDIK1L ; PDPK1 ; PDPK2P ; PEAK1 ; PEAK3 ; PHKG1 ; PHKG2 ; PIK3R4 ; PIM1 ; PIM2 ; PIM3 ; PINK1 ; PKDCC ; PKMYT1 ; PKN1 ; PKN2 ; PKN3 ; PLK1 ; PLK2 ; PLK3 ; PLK4 ; PLK5 ; PNCK ; POMK ; PRKAA1 ; PRKAA2 ; PRKACA ; PRKACB ; PRKACG ; PRKCA ; PRKCB ; PRKCD ; PRKCE ; PRKCG ; PRKCH ; PRKCI ; PRKCQ ; PRKCZ ; PRKD1 ; PRKD2 ; PRKD3 ; PRKG1 ; PRKG2 ; PRKX ; PRKY ; PRPF4B ; PSKH1 ; PSKH2 ; PTK2 ; PTK2B ; PTK6 ; PTK7 ; PXK ; RAF1 ; RET ; RIOK1 ; RIOK2 ; RIOK3 ; RIPK1 ; RIPK2 ; RIPK3 ; RIPK4 ; RNASEL ; ROCK1 ; ROCK2 ; ROR1 ; ROR2 ; ROS1 ; RPS6KA1 ; RPS6KA2 ; RPS6KA3 ; RPS6KA4 ; RPS6KA5 ; RPS6KA6 ; RPS6KB1 ; RPS6KB2 ; RPS6KC1 ; RPS6KL1 ; RSKR ; RYK ; SBK1 ; SBK2 ; SBK3 ; SCYL1 ; SCYL2 ; SCYL3 ; SGK1 ; SGK2 ; SGK223 ; SGK3 ; SIK1 ; SIK1B ; SIK2 ; SIK3 ; SLK ; SNRK ; SPEG ; SRC ; SRMS ; SRPK1 ; SRPK2 ; SRPK3 ; STK10 ; STK11 ; STK16 ; STK17A ; STK17B ; STK24 ; STK25 ; STK26 ; STK3 ; STK31 ; STK32A ; STK32B ; STK32C ; STK33 ; STK35 ; STK36 ; STK38 ; STK38L ; STK39 ; STK4 ; STK40 ; STKLD1 ; STRADA ; STRADB ; STYK1 ; SYK ; TAOK1 ; TAOK2 ; TAOK3 ; TBCK ; TBK1 ; TEC ; TEK ; TESK1 ; TESK2 ; TEX14 ; TGFBR1 ; TGFBR2 ; TIE1 ; TLK1 ; TLK2 ; TNIK ; TNK1 ; TNK2 ; TNNI3K ; TP53RK ; TRIB1 ; TRIB2 ; TRIB3 ; TRIO ; TSSK1B ; TSSK2 ; TSSK3 ; TSSK4 ; TSSK6 ; TTBK1 ; TTBK2 ; TTK ; TTN ; TXK ; TYK2 ; TYRO3 ; UHMK1 ; ULK1 ; ULK2 ; ULK3 ; ULK4 ; VRK1 ; VRK2 ; VRK3 ; WEE1 ; WEE2 ; WNK1 ; WNK2 ; WNK3 ; WNK4 ; YES1 ; ZAP70
Damage during the emplacement surgery Damage during a thoracic surgery Chemical degradation of the silicone shell of the prosthesis Trauma: blunt trauma, penetrating trauma, blast trauma Mechanical pressure, e.g. capsular contracture and mammogram breast examination As a Class III medical device, the breast implant is an industrial product that eventually fails because of age and design flaws of material and manufacture; thus the rupture-and-deflation of a prosthetic breast is a medical-device failure resolved with the surgical explantation and replacement of the failed prosthetic breast with a new model of prosthetic breast. In that light, the Food and Drug Administration informed the women of the U.S. that breast implants are medical devices of finite shelf-life that wear out and fail. That the longer a woman has breast implants in her body — either saline solution or silicone gel — the greater the statistical likelihood of her experiencing the medical complications of the rupture-and-deflation failure of her prosthetic breasts. For Second-generation prosthetic breasts (silicone shell, single-lumen) designed in the 1970s, the rupture-deflation defect occurred at the rate of eight to fifteen per cent (8–15%) at the ten-year mark after the surgery; which occurred among fifteen to thirty per cent (15–30%) of the cohort of mammoplasty patients. The study Safety and Effectiveness of Mentor's MemoryGel Implants at 6 Years (2009) reported a medical-device rate of failure of one-point-one per cent (1.1%) at the six-year mark after the surgery.
Skeletal muscle, is a type of striated muscle, composed of muscle cells, called muscle fibers, which are in turn composed of myofibrils. Myofibrils are composed of sarcomeres, the basic building blocks of striated muscle tissue. Upon stimulation by an action potential, skeletal muscles perform a coordinated contraction by shortening each sarcomere. The best proposed model for understanding contraction is the sliding filament model of muscle contraction. Within the sarcomere, actin and myosin fibers overlap in a contractile motion towards each other. Myosin filaments have club-shaped myosin heads that project toward the actin filaments, and provide attachment points on binding sites for the actin filaments. The myosin heads move in a coordinated style; they swivel toward the center of the sarcomere, detach, and then reattach to the nearest active site of the actin filament. This is called a ratchet-type drive system. This process consumes large amounts of adenosine triphosphate (ATP), the energy source of the cell. ATP binds to the cross-bridges between myosin heads and actin filaments. The release of energy powers the swiveling of the myosin head. When ATP is used, it becomes adenosine diphosphate (ADP), and since muscles store little ATP, they must continuously replace the discharged ADP with ATP. Muscle tissue also contains a stored supply of a fast-acting recharge chemical, creatine phosphate, which when necessary can assist with the rapid regeneration of ADP into ATP. Calcium ions are required for each cycle of the sarcomere.
The Korean People's Revolutionary Army (Korean: 조선인민혁명군; KPRA) was a purported partisan group which North Korea claims fought against the Japanese rule in Korea. North Korean historiography claims that the KPRA was founded on 25 April 1932 by Kim Il Sung.
Sources: en.wikipedia.org
Gindilis, there are two criteria for a signal to be called artificial: one related to the artificial nature of the source and the other related to a particular radiation, intentionally designed to ensure communication and facilitate detection. Only Type II or III civilizations can communicate using isotropic transmissions that allow omnidirectional reception. In a 1 MHz band (which requires about 1024 watts), detection of signals from a Type II civilization is possible up to 1,000 light-years away, while signals from a Type III civilization are detectable virtually throughout the observable Universe. However, building an omnidirectional transmitter powerful enough to transmit over a range of 1,000 light years would take several million years. According to V.S. Troitsky, the energy required and the limitations in its production would be two obstacles to completing this project in a reasonable time. For Zoltan Galántai, we would not be able to distinguish between an intelligent extraterrestrial signal and a signal of natural origin. Therefore, he does not believe that Type II, III or even IV civilizations can be detected. Even if humanity reaches Type IV, it will not be able to detect another supercivilization of a similar level, and we will consider their changes in the universe to be the result of natural causes. Thus, there may be many Type IV civilizations in the universe, but none of them will be able to detect the others. Moreover, the dimensions of the universe make these supercivilizations like islands far from the others, which Dyson defines as a "Carroll Universe".
These last terms are mostly determined by the interfacial layer as this is the outermost part of the particle, thereby determining the surface interactions. For example, the bridging term only plays a role when the molecules in the interfacial layer tend to polymerize. In the case of nanoparticles made of a crystal, quantum mechanical interactions would be expected, but due to the interfacial layer the cores cannot get close enough to each other, and therefore these interactions are neglectable. An illustrative limit-case are non-charged semiconducting quantum dots (QD) in an ideal fluid. Due to the ideal fluid there is no difference between the QD–QD interaction and the QD–fluid interaction. For only the VDW interaction is of importance in the interaction between the interfacial layers, which are made of the superfluid, and other interfacial layers or the solvent. This means there is no attraction between the particles, so they can be accurately described using the Hard Sphere model.
The industry was also affected by disputes about whether grain or blended whisky was worthy of the name, with an adverse decision in North London Police Court in 1905. A Royal Commission on Whisky and other Potable Spirits was appointed in 1906 and reported in 1909 with a victory for the grain distillers and blenders. The industry was further affected by World War I, Prohibition in the United States and later, by the Great Depression; many of the companies closed and never re-opened. Of the 159 distilleries operating in the boom years around 1900, only 15 survived to 1933. During the 1970s there was a new boom in Scotch whisky production that led to an overproduction in the early 1980s. Starting in 1981 whisky distilleries slashed production by a third and kept it low for a decade. During that time many distilleries closed. Banff, Brora, Coleburn, Convalmore, Dallas Dhu, Glen Albyn, Glenesk, Glen Flagler, Glenlochy, Glen Mhor, Glenugie, Glenury, Millburn, North Port, Port Ellen and St Magdalene were mothballed, shut down or demolished. Since the 2010s, Scotch whisky has entered a new phase of growth with new distilleries like Ardnahoe and Borders opening and older distilleries like Brora, Port Ellen and Rosebank reopening.
== Side effects == Protriptyline shares side effects common to all TCAs. The most frequent of these are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, decreased coordination, anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal problems. Other more complicated side effects include; chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; sudden numbness or weakness, especially on one side of the body; sudden headache, confusion, problems with vision, speech, or balance; hallucinations, or seizure (convulsions); easy bruising or bleeding, unusual weakness; restless muscle movements in your eyes, tongue, jaw, or neck; urinating less than usual or not at all; extreme thirst with headache, nausea, vomiting, and weakness; or feeling light-headed or fainting. Dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. Patients may also chew sugarless gum or suck on sugarless candy in order to increase the flow of saliva. Some artificial saliva products may give temporary relief. Men with prostate enlargement who take protriptyline may be especially likely to have problems with urinary retention. Symptoms include having difficulty starting a urine flow and more difficulty than usual passing urine.
1-Heneicosanol is the C21 member of the series of linear, saturated primary alcohols derived formally from heneicosane by substitution of a terminal hydrogen atom with a hydroxyl group. It is classified as a long-chain fatty alcohol. Commercial material is typically obtained as a white powder or low-melting wax with a reported melting range of about 68–71 °C. A safety data compilation and estimation methods indicate a high normal boiling point of around 366 °C at 760 mmHg, consistent with its long carbon chain. The compound has very low solubility in water and a high octanol/water partition coefficient (log P), reflecting its pronounced hydrophobic character.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.